These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 34155812)

  • 1. Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.
    Chen W; Liu Y; Li Y; Dang H
    ESC Heart Fail; 2021 Oct; 8(5):3783-3790. PubMed ID: 34155812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
    El-Battrawy I; Demmer J; Abumayyaleh M; Crack C; Pilsinger C; Zhou X; Mügge A; Akin I; Aweimer A
    ESC Heart Fail; 2023 Apr; 10(2):943-954. PubMed ID: 36479630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome.
    Fröb EJ; Sindermann JR; Reinecke H; Tuleta I
    Adv Clin Exp Med; 2022 May; 31(5):475-487. PubMed ID: 35092651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study.
    Wang C; Lin Z; Miao D; Zhang H; Fu K; Zhang X; Xiao J; Hu Y; Sun Y; Wang F; Lu H; Ji X
    ESC Heart Fail; 2023 Jun; 10(3):1961-1971. PubMed ID: 36991256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease.
    Niu CY; Yang SF; Ou SM; Wu CH; Huang PH; Hung CL; Lin CC; Li SY
    J Am Heart Assoc; 2022 Sep; 11(18):e026407. PubMed ID: 36062622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
    Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
    Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease.
    Lee S; Oh J; Kim H; Ha J; Chun KH; Lee CJ; Park S; Lee SH; Kang SM
    ESC Heart Fail; 2020 Jun; 7(3):1125-1129. PubMed ID: 32153122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
    JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study.
    Yang Y; Shen C; Lu J; Fu G; Xiong C
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):177-182. PubMed ID: 34711748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
    Naser N; Kulić M; Jatić Z
    Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction.
    Jiang J; Gao J; Zhang X; Li Y; Dang H; Liu Y; Chen W
    Front Cardiovasc Med; 2023; 10():1097066. PubMed ID: 37034349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
    Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
    J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis.
    Bouali Y; Galli E; Paven E; Laurin C; Arnaud H; Oger E; Donal E
    Adv Clin Exp Med; 2022 Feb; 31(2):109-119. PubMed ID: 34918885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.